Red Cell Flexibility and Platelet Aggregation in Patients with Chronic Obstructive Vascular Disease (COAD) and Study of Therapeutic Approaches

Ambrus, J. L.; Ambrus, C. M.; Taheri, S. A.; Gastpar, H.; Reddington, M. M.; Taheri, P.; Kahn, E. A.; Schattman, G. L.; Dean, L. S.; Moore, R. H.
July 1984
Angiology;Jul1984, Vol. 35 Issue 7, p418
Academic Journal
The red blood cell flexibility was studied in the blood of twenty patients with severe peripheral vascular disease and twenty matched controls. Patients exhibited significantly less red cell flexibility than controls. In both groups there was an inverse relationship between age and red cell flexibility. No correlation was found between red cell flexibility and sex or smoking history. Pentoxifylline, a xanthine derivative which Inhibits phosphodiesterases and platelet aggregation, was found to increase red cell flexibility. This effect of the drug was greater on red cells with impaired flexibility than on normal cells. Various prostaglandins by contrast were found to decrease red cell flexibility, this could be compensated for by pentoxifylline. Forty patients with COAD were treated intravenously with PgE1. Significant inhibition of platelet aggregation and clinical improvement was noticed. It is suggested that combinations of PgE1 and pentoxifylline should be explored in clinical studies.


Related Articles

  • In-vitro stability and aggregatory effect of ethanol extract leaves of Sida acuta Burm F. on human erythrocyte. Eze, Obioma Benedeth; Nwodo, Okwesili Fred // Journal of Experimental & Integrative Medicine;2016, Vol. 6 Issue 3, p134 

    Aim: This study aims to evaluate the membrane stability, phospholipase A2 activity, prostaglandin synthase activity and aggregatory effect of ethanol leaves extract of Sida acuta Burm F. using an in-vitro heamolytic assay. Materials and methods: Two milliliters of blood collected from a healthy...

  • Pentoxifylline Studies.  // Life Extension;Jan2002, Vol. 8 Issue 1, p18 

    Provides information on pentoxifylline (PTX), a prescription drug approved by the U.S. Food and Drug Administration to treat peripheral vascular disease. Standard dosage; Findings of a controlled study on human diabetics with advanced renal failure; Effect of PTX in a group of pediatric lupus...

  • Combination Antiplatelet Therapy in Patients with Peripheral Vascular Bypass Grafts. Smout, Jonathan D.; Mikhailidis, Dimitri P.; Shenton, Brian K.; Stansby, Gerard // Clinical & Applied Thrombosis/Hemostasis;Jan2004, Vol. 10 Issue 1, p9 

    Peripheral bypass graft occlusion occurs in approximately 25% of cases in the 5 years following surgery; hence, therapies directed at reducing the tendency toward thrombotic occlusion are of clinical importance. This trial was conducted to determine if the addition of clopidogrel to aspirin...

  • Failure of Pentoxifylline or Cilostazol to Improve Blood and Plasma Viscosity, Fibrinogen, and Erythrocyte Deformability in Claudication. Dawson, David L.; Qintian Zheng; Worthy, Sue A.; Charles, Brandie; Bradley, Donald V. // Angiology;Sep/Oct2002, Vol. 53 Issue 5, p509 

    Peripheral artery disease is associated with altered blood theologic properties, including increased viscosity and decreased red blood cell (RBC) deformability. Pentoxifylline and cilostazol are available therapies for intermittent claudication. Improvement of blood viscosity and erythrocyte...

  • ED agent does not alter bleeding time in men on asprin. Rutledge, Barbara J. // Urology Times;Dec2003, Vol. 31 Issue 12, p14 

    Reports on the finding that the highest dose of a phosphodiesterase (PDE) type-5 inhibitor for erectile dysfunction does not increase bleeding time in healthy volunteers taking a regimen of low-dose aspirin. Inhibition of platelet aggregation by PDE; Evaluation of the effects of low-dose,...

  • Increase in antiplatelet effects of prostaglandins by a-tocopherol and quercetin. Kobzar, Gennadi; Mardla, Vilja; Samel, Nigulas // Proceedings of the Estonian Academy of Sciences, Biology, Ecolog;Jun2005, Vol. 54 Issue 2, p120 

    Prostacyclin (PGI2) and prostaglandin E1 (PGE1) are effective inhibitors of platelet aggregation. Therefore, they are attractive compounds for the treatment of cardiovascular diseases. However, their use is restricted due to unwanted side effects. a-Tocopherol and quercetin are weak antiplatelet...

  • Prostacyclin. Vane, J. R. // Journal of the Royal Society of Medicine;Apr1983, Vol. 76 Issue 4, p245 

    The article discusses the properties and the use of prostacyclin. Prostacyclin is generated enzymically from the prostaglandin endoperoxide PGH2 by blood vessel microsomes or fresh vascular tissue. It is a potent vasodilator and the most potent endogenous inhibitor of platelet aggregation. It...

  • ERYTHROCYTES FUNCTIONAL PARAMETRES CHANGING UNDER APITHERAPY OF NEUROLOGICAL PATIENTS. Krylov, V. N.; Goustov, A. V.; Deriugina, A. V.; Antipenko, E. A. // Mellifera;2007, Vol. 7 Issue 13/14, p27 

    By including of the bee venom in the therapeutic complex treatment of the patients with chronic cerebral ischemia (CCI) and chronic back pain (BP) we established that clinical picture of patients recovering patients coincided with rising EPEM, decreasing agregability and blood clotting time.

  • Pharmacotherapy can be useful in treating peripheral arterial disease, but options are limited.  // Drugs & Therapy Perspectives;Apr2013, Vol. 29 Issue 4, p108 

    Effective pharmacological options for peripheral arterial disease are limited. For intermittent claudication that persists despite exercise training, cilostazol is the first-line therapy and pentoxifylline is a second-line option, while the agents potentially useful for critical limb ischaemia...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics